Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Rona Yaeger,Nataliya V. Uboha,Meredith S. Pelster,Tanios S. Bekaii-Saab,Minal Barve,Joel Saltzman,Joshua K. Sabari,Julio A. Peguero,Andrew Scott Paulson,Pasi A. Jänne,Marcia Cruz-Correa,Kenna Anderes,Karen Velastegui,Xiaohong Yan,Hirak Der-Torossian,Samuel J. Klempner,Scott E. Kopetz
DOI: https://doi.org/10.1158/2159-8290.cd-24-0217
IF: 28.2
2024-04-09
Cancer Discovery
Abstract:Adagrasib, an irreversible, selective KRASG12C inhibitor, may be an effective treatment in KRASG12C-mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRASG12C-mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four patients received adagrasib plus cetuximab. With a median follow-up of 11.9 months, ORR was 34.0%, disease control rate was 85.1%, and median duration of response was 5.8 months (95% confidence interval [CI], 4.2–7.6). Median progression-free survival was 6.9 months (95% CI, 5.7–7.4) and median overall survival was 15.9 months (95% CI, 11.8–18.8). Treatment-related adverse events (TRAEs) occurred in all patients; grade 3–4 in 27.7% and no grade 5. No TRAEs led to adagrasib discontinuation. Exploratory analyses suggest circulating tumor DNA may identify features of response and acquired resistance. Significance: Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRASG12C-mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRASG12C mutations in patients with colorectal cancer.
oncology
What problem does this paper attempt to address?